N@N

ARWR, RARE, SIGI, ALXN, ABIO, RAX, Expected to Trade Lower After Bearish Insider Trading

^{Published on 2016-10-19 04:46:10 - WOPRAI}
 

October 19, 2016 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring top insider trading patterns and these stocks are the most likely to trade Lower in the next 6 months. Arrowhead Research Corporation (NASDAQ:ARWR), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Selective Insurance Group Inc. (NASDAQ:SIGI), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), ARCA biopharma Inc. (NASDAQ:ABIO), Rackspace Hosting Inc. (NYSE:RAX) are all expected to go Lower as Sell signals have been generated by top insider trading patterns. The most important data elements considered when performing insider analysis are: Insiders Track Record - An insiders track record is best summarized by the Insider Score which ranges from 1 (least predictive) to 100 (most predictive) based on prior trading performance. In addition, the actual returns following the insiders prior trades are included to determine the potential magnitude of future returns. Insiders Role - Trades by higher-level insiders are generally more predictive than trades by lower level insiders. Higher-level insiders to include Chairman (CB), Chief Executive Officer (CEO), President (P), Chief Financial Officer (CFO), and Vice Chairman (VC).

The chart below displays the stocks expected to go Lower along with the insider name, position, predictive insider score, 6 month expected return and number of trading decisions included in the score.

  Symbol  Company Name                     Insider Name                     Role     Shares      Insider Score  Avg 6 Month Return  # of Dec. 
  ARWR    Arrowhead Research Corporation   Given, Douglass B M.D.           D        12,000      91             -54.4%              2         
  RARE    Ultragenyx Pharmaceutical Inc.   Kakkis, Emil D                   CEO      20,000      91             -31.5%              4         
  SIGI    Selective Insurance Group Inc.   Murphy, Gregory E                CEO      8,333       89             -8.1%               24        
  ALXN    Alexion Pharmaceuticals, Inc.    Thiel, Carsten                   O        4,584       75             -12.6%              4         
  ABIO    ARCA biopharma Inc.              Keuer, Thomas A                  CO       483         95             -28.8%              4         
  RAX     Rackspace Hosting Inc.           Roenigk, Mark W                  CO       5,000       83             -5.7%               27        

Arrowhead Research Corporation (NASDAQ:ARWR) - Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company, develops novel drugs to treat intractable diseases in the United States. The company utilizes its proprietary Dynamic Polyconjugate platform to develop targeted drugs based on the RNA interference mechanism that silences disease-causing genes. Its ARC-520, an RNAi-based therapeutic that is in Phase IIb clinical efficacy studies to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic, which is in Phase Ib clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. The company s pre-clinical stage drug candidates include ARC-521, an RNAi-based therapeutic for the treatment of chronic hepatitis B virus; ARC-F12, an RNAi-based therapeutic to treat hereditary angioedema and thromboembolic diseases; ARC-HIF2, an RNAi-based therapeutic to treat renal cell carcinoma; and ARC-LPA, an RNAi-based therapeutic for the treatment of cardiovascular diseases. It also holds patents related to Adipotide for the treatment of obesity and related metabolic disorders. The company has research collaboration and license agreement with Shire AG to develop and commercialize targeted peptide-drug conjugates; and a collaborative agreement with Spring Bank Pharmaceuticals, Inc. to perform studies on Arrowhead s ARC-520 and Spring Bank s SB 9200 for the treatment of chronic Hepatitis B. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California..

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - RARE Hospitality International, Inc. (RARE Hospitality), incorporated in December 1982, and its subsidiaries operate and franchise restaurants. As of February 21, 2006, the Company operated and franchised 303 restaurants, including 247 LongHorn Steakhouse restaurants, 23 The Capital Grille restaurants and 31 Bugaboo Creek Steak House restaurants, as well as two additional restaurants (the specialty restaurants), Hemenway's Seafood Grille & Oyster Bar (Hemenway's) and The Old Grist Mill Tavern.

LongHorn Steakhouse

LongHorn Steakhouse restaurants are casual dining, full-service establishments serving both lunch and dinner. With locations spread throughout 25 states primarily in the Eastern half of the United States, LongHorn Steakhouse restaurants feature a variety of items, including signature steaks, as well as salmon, shrimp, chicken, ribs, pork chops, burgers and prime rib. The Company's prototypical LongHorn Steakhouse has an average seating capacity of approximately 188 seats in approximately 5,600 square feet of space. It leases the sites for all but 68 of its LongHorn Steakhouse restaurants in operation. The Company also owns four sites for restaurants under construction and owns the sites for two restaurants with construction scheduled to begin later in 2006.

The Capital Grille

The Capital Grille is located in major metropolitan cities in the United States. The Capital Grille offers dry aging steaks on premises and fresh seafood. The Capital Grille restaurant development strategy includes the use of sites that are historic or unique in nature. Accordingly, the Company utilizes methods to balance control of the construction costs with the retention of the unique ambiance of each location. The Company leases all of its The Capital Grille restaurant sites. Three The Capital Grille restaurants were opened in 2005.

Bugaboo Creek Steak House

Primarily located in states on the Eastern seaboard, Bugaboo Creek Steak House restaurants attract guests of all ages with a rustic decor reminiscent of an authentic Rocky Mountain lodge. Bugaboo Creek Steak House restaurants offer a variety of menu offerings including seasoned steaks, prime rib, smoked baby-back ribs, spit roasted half chicken, grilled salmon and shrimp. The Company continues to develop and refine the Bugaboo Creek Steak House restaurant design with the objective of reducing the capital expenditure required for new restaurant construction and reducing ongoing operating costs. This modified design is smaller than earlier designs and utilizes approximately 6,400 square feet with a capacity of approximately 230 seats. All of the Bugaboo Creek Steak House restaurants opened in 2005 were located on leased property..

Selective Insurance Group Inc. (NASDAQ:SIGI) - Selective Insurance Group, Inc., together with its subsidiaries, provides insurance products and services in the United States. It operates in four segments: Standard Commercial Lines, Standard Personal Lines, Excess and surplus (E&S) Lines, and Investments. The company s products and services include property insurance, which covers the financial consequences of accidental loss of an insured s real and/or personal property; and casualty insurance that covers the financial consequences of employee injuries in the course of employment, and bodily injury and/or property damage to a third party as a result of an insured s negligent acts, omissions, or legal liabilities. Its products and services also comprise flood insurance, which covers property losses. The company offers its insurance products and services to businesses, non-profit organizations, local government agencies, and individuals through independent retail insurance agents and brokers, and wholesale general agents. In addition, it invests in the premiums collected by standard commercial lines, standard personal lines, and E&S lines; and fixed income securities, common stocks, preferred securities, and alternative investments portfolio. Selective Insurance Group, Inc. was founded in 1925 and is headquartered in Branchville, New Jersey..

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) - Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem's proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna's messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut..

ARCA biopharma Inc. (NASDAQ:ABIO) - ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in patients with heart failure and left ventricular with reduced left ventricular ejection fraction. The company also engages in developing recombinant Nematode Anticoagulation Protein c2, a therapy for the disease syndrome caused by infection from hemorrhagic fever viruses and other pathogens. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B/Phase 3 clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado..

Rackspace Hosting Inc. (NYSE:RAX) - Rackspace Hosting, Inc., through its subsidiaries, provides managed cloud services in the business information technology (IT) market worldwide. The company provides a portfolio of integrated IT solutions for business needs across two primary form factors, dedicated cloud and private clouds, and managed public clouds. Its dedicated cloud services comprise a customer portal and other management tools for managing the data center, network, hardware devices, and operating system software; public cloud services include multi-tenant pools of computing resources delivered on-demand over the Internet; and private cloud services consist of a pool of computing resources for a specific customer. The company also provides hybrid hosting, which enables customers to utilize any combination of dedicated and pooled resources and to manage them through its RackConnect service. Its managed support services include dedicated customer care and technical support, such as operating system patching, application monitoring, network and firewall configurations, and identity management. The company also offers specialized services for certain applications, including e-commerce and Web content management sites; business-productivity applications, such as email and collaboration; and data stores, as well as customer services. It sells its services through direct sales teams, third party channel partners, and online ordering. The company was founded in 1998 and is headquartered in San Antonio, Texas..

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net